We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
LAVA Therapeutics NV | NASDAQ:LVTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.07 | -2.26% | 3.03 | 2.95 | 9.87 | 3.10 | 2.9601 | 3.10 | 47,455 | 05:00:01 |
By Colin Kellaher
LAVA Therapeutics N.V. on Friday said the U.S. Food and Drug Administration granted orphan-drug designation to LAVA-051, the most advanced product candidate from its Gammabody platform, for the treatment of chronic lymphocytic leukemia.
The Utrecht, Netherlands, clinical-stage biotechnology company said enrollment is underway in a Phase 1/2a clinical trial of LAVA-051 for the treatment of relapsed and/or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing-exclusivity period against competition.
LAVA said it expects data from the Phase 1 dose escalation phase of the study in the first half of 2022, with top-line clinical data from the Phase 2a expansion cohorts expected in the second half.
Shares of LAVA, which closed Thursday at $7.63, rose 7.6% in premarket trading Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 15, 2021 07:48 ET (11:48 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year LAVA Therapeutics NV Chart |
1 Month LAVA Therapeutics NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions